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ABSTRACT 
 
 
 Peptides and proteins are imperative for the human body and play crucial roles in 
governing various bio-chemical processes. Recent advances in molecular biology and 
biochemistry helped in understanding the role of these endogenous macromolecules in 
different pathological and disease conditions. Currently, small molecule drugs 
(<900dalton) in comparison to the therapeutic peptides and proteins-based drugs (TPP) 
dominate pharmaceutical market. However, the game is changing with the recent 
advances of biotechnological tools like recombinant DNA technology, solid phase 
protein synthesis etc., which enabled large-scale production of therapeutic peptides and 
proteins. The Success of Human Insulin, the first FDA approved commercial 
recombinant protein based therapeutic in 1982, revolutionized the field of TPPs. The 
number of FDA approved TPPs reached about to ~239 in 2017 compared to where it was 
only ~130 in 2008.  
 
Rapid progress in this sector can be attributed to several advantages of proteins 
and peptides over small molecule drugs both financially and clinically. From a clinical 
perspective, proteins and peptides are inherently more specific to the target site than the 
small molecules drugs, which lead to less interferences with normal biological system of 
the patient and caused minimal off-target side effects. A handful of proteins which are 
used for different clinical complications are less immunogenic because they are produced 
in the body naturally. Furthermore, proteins and peptides also take part in several 
complex and complicated biological processes, which is difficult to be to be mimicked by 
the small molecule drugs. From a financial standpoint, median total pre-market 
development times were shorter for biologics (10.6 years) than the small molecules drugs 
(12.6 years) estimated using Merck Index. In 2009, US Congress passed the Biologics 
Price Competition and Innovation Act (BPCIA) which gave new biologics 12 years of 
guaranteed exclusivity.  
 
The most commonly utilized routes for administering TPPs are I.V, I.P or I.M 
injections, which largely suffer from patient compliances. There are ~350 TPPs under 
clinical development and among them only 2 are given orally which is Interferon-α and 
Human growth hormone. Currently, most efforts in both industry and academia are 
centered around enhancing bioavailability of orally administered TPPs which typically 
are less than 1%. Oral administration is the non-invasive, most preferred route of drug 
administration for the patients. Furthermore, oral dosage forms are cheaper to 
manufacture as well as to administer, because they do not need to be produced under 
sterile conditions or administered in clinics.  However, unfavorable physicochemical 
characteristics of TPPs like high molecular weight, hydrophilicity, poor stability in the 
physiological conditions, short biological half-life, low permeability through the 
epithelial barrier in the small intestine put up a massive barrier in the development of 
orally available dosage forms of TPPs. In this review, we will discuss the challenges 
associated with oral delivery of TPPs and the ongoing efforts to solve them. 
  
 vi 
TABLE OF CONTENTS 
 
CHAPTER 1. INTRODUCTION .....................................................................................1 
CHAPTER 2. CHALLENGES ASSOCIATED WITH ORAL DELIVERY OF 
PEPTIDES AND PROTEINS ...........................................................................................3 
Enzymatic Barriers of the Digestive System  ..................................................................3 
Transport Across the Epithelial Membrane in The Small Intestine .................................3 
CHAPTER 3. STRATEGIES FOR ENHANCING ORAL DELIVERY OF 
PROTEINS AND PEPTIDES ...........................................................................................6 
Permeation/Absorption Enhancers ..................................................................................6 
Enzyme Inhibitors ............................................................................................................7 
Structural Modifications ..................................................................................................9 
PEGlyation .....................................................................................................................10 
Mucoadhesive Polymeric Systems ................................................................................11 
Cell Penetrating Peptides ...............................................................................................12 
Enteric Coating for Oral Delivery of Peptides ...............................................................14 
Liposomes ......................................................................................................................15 
Microspheres ..................................................................................................................16 
Microparticles/Nanoparticles .........................................................................................17 
CHAPTER 4. CLINICAL INVESTIGATION OF ORAL PEPTIDES AND 
PROTEINS .......................................................................................................................20 
Eligen® by Emisphere ....................................................................................................20 
CLEC by Altus Pharmaceuticals ...................................................................................20 
BioOral by BioSante Pharmaceuticals ...........................................................................20 
Oral-LynTM by Generex .................................................................................................21 
HIM2 by Nobex and Biocon ..........................................................................................21 
OraldelTM (ANL010) by Apollo Life Sciences ..............................................................21 
AI-401 by Eli-Lilly and Autoimmune Inc. ....................................................................22 
Orasome by Endorex Corporation .................................................................................22 
GIPET® by Merrion Pharma and Novo Nordisk ...........................................................22 
Oramed by Oramed Pharmaceuticals ............................................................................23 
PeptelligenceTM from Unigene Laboratories, Enteris Biopharma ..................................23 
CHAPTER 5. CONCLUSIONS AND FUTURE DIRECTIONS ................................24 
LIST OF REFERENCES ................................................................................................25 
VITA..................................................................................................................................35 
 
 
 
  
 vii 
LIST OF TABLES 
 
Table 3-1. Permeation enhancers used in oral TPP formulation ......................................8 
Table 3-2. Strategies for improving oral bioavailability of TPPs ..................................19 
 
 
 
  
 viii 
LIST OF FIGURES 
 
Figure 2-1. Key contributors in G.I.T. governing oral delivery of TPPs ..........................5 
 
 
  
 ix 
LIST OF ABBREVIATIONS 
 
 
TPPs Therapeutic peptide and protein-based drugs 
I.V. Intravenous 
I.P. Intraperitoneal 
I.M. Intramuscular 
G.I.T. Gastrointestinal tract 
CPP Cell penetrating peptides 
NDA New drug application 
BLA Biological license application 
 
 
 
 
 1 
CHAPTER 1.    INTRODUCTION 
 
 
Peptide and proteins are most important part of the body which governs the 
functions of human body. In last few year, significant progress in the field of molecular 
biology and biochemistry have led to better understanding of these molecules role in 
different disease conditions starting from neurological disorders to cancer. Currently, 
small molecule drugs (<900dalton) have more prominent presence in the pharmaceutical 
market than the therapeutic peptide and protein-based drugs (TPP) dominate 
pharmaceutical drug market. However, the game is changing with the recent advances of 
biotechnological tools like recombinant DNA technology, solid phase protein synthesis 
etc. which enabled large-scale production of therapeutic peptide and proteins [1]. 
Success of Human Insulin, first FDA approved commercial recombinant protein based 
therapeutic in 1982 revolutionized the field of TPPs [2]. Over the next three decades, 
domain of TPPs have grown significantly in both academia and industry. In 2018, 
FDA’s Center for Drug Evaluation and Research (CDER) approved 17 BLAs (biologics 
license application), which was highest in last two decades. Number of FDA approved 
TPPs reached to ~239 in 2017 where as it was only ~130 in 2008 [3, 4]. According to 
the report by Zion market research, global peptide based therapeutics market was 
estimated at approximately USD 23.06 billion in 2017 and anticipated to reach around 
USD 43.26 billion by 2024 [5]. The global oral proteins and peptides market is 
estimated around USD 643 million and likely to grow around $8,233 million by 2028 
[6]. 
 
Rapid progress in this sector can be attributed to proteins and peptides several 
advantages over small molecule drugs both financially and clinically. From a clinical 
perspective, proteins and peptides are inherently more specific to the target site than the 
small molecule drugs, which led to less interference with normal biological system of 
the patient and cause minimal off-target side effects. A handful of proteins which are 
used for different clinical complications are less immunogenic because they are 
produced in the body naturally. Furthermore, proteins and peptides also take part in 
several complex and complicated biological processes, which is difficult to be mimicked 
by the small molecule drugs. From a financial standpoint, median total pre-market 
development times were shorter for biologics (10.6 years) than the small molecule drugs 
(12.6 years) estimated using Merck Index. In 2009, US Congress passed the Biologics 
Price Competition and Innovation Act (BPCIA) which gave new biologics 12 years of 
guaranteed exclusivity [7]. Thus, the road to the commercial market is comparatively 
easier for the biologics in compared to the small molecule drugs. 
 
The most commonly utilized routes for administering TPPs are I.V, I.P or I.M 
injections which largely suffers from patient compliances. There are ~350 TPPs under 
clinical development and among them only 2 are given orally e.g. Interferon-α and 
Human growth hormone. Currently most efforts in both the Pharmaceutical industry and 
academia are centered to enhance bioavailability of orally administered TPPs which 
typically less than 1% [8]. Oral administration is the most preferred route of drug 
administration for the patients. Advantages of oral administration also includes 
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avoidance of pain and discomfort with injections. Furthermore, oral dosage forms are 
cheaper to manufacture as well as administer because they do not need to be produced 
under sterile conditions or administered in a clinic [9].However, unfavorable 
physicochemical characteristics of TPPs like high molecular weight, hydrophilicity, 
poor stability in the physiological conditions, short biological half-life, low permeability 
through the epithelial barrier in the small intestine put up a huge barrier for the 
development of orally available dosage forms of TPPs [10]. An ideal oral drug delivery 
platform for TPPs should retain its therapeutic activity and protect it from the 
proteolysis and heavily acidic environment of the stomach before releasing it in its 
active form in the neutral environment of the intestine to get absorbed in the blood 
stream. In this review, we will discuss the challenges associated with oral delivery of 
TPPs and ongoing efforts to solve them. 
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CHAPTER 2.    CHALLENGES ASSOCIATED WITH ORAL DELIVERY OF 
PEPTIDES AND PROTEINS 
 
 
Enzymatic Barriers of the Digestive System 
 
Orally administered TPPs and food face similar hurdles while passing from the 
mouth to the anus through G.I.T (esophagus, stomach, small intestine, and large intestine) 
before getting absorbed in the small intestine. That is why understanding of the anatomy 
and physiology of the different components of the G.I.T is crucial for successful design 
of oral dosage formulation of TPPs. Most of the nutrients are absorbed through the small 
intestine, while absorption in mouth, stomach is very minimum [11]. In mouth, saliva is 
mixed with the ingested food and helps in smooth movement to esophagus. Protein 
degradation in mouth and esophagus is minimal though mouth saliva contains amylase, 
lipase which helps in digestion of starch and fat respectively [12]. Acidic environment 
(pH 1.5-3.5) of the stomach is maintained by the gastric acid (hydrochloric acid, 
potassium chloride, and sodium chloride) which is secreted from oxyntic cells [13]. 
Acidic environment destabilizes protein and peptide structure and exposes peptide bonds 
for pepsin degradation. The major enzymatic degradation of the proteins and peptides 
occur in the small intestine which contains significant amount of proteases from the 
pancreas and cellular proteases from the mucosal cells [14]. 
 
Intestinal enzymes like pepsin, trypsin, chymotrypsin, elastase with the aid of 
acidic environment of stomach primarily facilitate protein and peptide breakdown and 
then convert them into smaller amino acid units [15, 16]. Pepsinogen, in presence of the 
hydrochloric acid present in the gastric juice is converted to pepsin which is involved in 
breaking down the peptide bonds of amino acids (L-phenylalanine, L-tyrosine, L-
tryptophan, and L-leucine) adjacent to a hydrophobic amino acid [17]. Thus, the 
gastrointestinal enzymes put up a huge challenge for oral delivery of TPPs. Encapsulation 
in sustained releasing nanoparticles or enteric coating is widely used to protect TPPs 
from the enzymatic degradation [18]. A no of factors such as a) molecular weight, b) 
hydrophilicity, c) Hydrogen bond donor/accepting potential, D) higher no of enzyme 
susceptible groups E) Low flexibility of the structure can be accountable for protein 
degradation in the G.I.T. 
 
 
Transport Across the Epithelial Membrane in The Small Intestine 
 
Epithelial barrier can possibly be crossed via three different mechanisms. They 
are paracellular transport, passive transcellular transport and active carrier mediated 
transcellular transport. Paracellular (transport of the molecules between the cells) or 
transcellular pathways (transport of the molecules into or across the cells) are most 
common by which molecules passively diffuse through the epithelial membrane. Most 
TPPs are highly hydrophilic in nature with a minute Log P value (<0) and expected to 
follow the paracellular pathways. Three different junctions are present in the intestinal 
epithelial lining: desmosomes or zonulae adherens, tight junctions or zonulae occludens, 
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and gap junctions [19]. Tight junctions, present between neighboring epithelial cells puts 
up a significant challenge for the paracellular transportation of large molecules (>100-
200 Da) across the intestinal epithelium [20]. Typically molecules with a radius not larger 
than 11-15Å are reported to pass through the aqueous pores of tight junctions [21-23]. 
Absorption via paracellular pathway in small intestine found to be limited because small 
surface area estimated to be about ~0.01% total area of the small intestine is available for 
absorption. Furthermore, charge on TPPs must also be taken into consideration along 
with size and hydrophilicity as the proteins that form the tight junction has polar amino 
acids and ionizable side chains which give it a negative net charge [24].  Increased 
concentrations of intracellular Ca2+ , cAMP+ decreases permeation of molecules at the 
tight junction [25].  
 
Vaishali and co-workers have found paracellular pathway to be cation-selective 
where cations of weak bases showed a faster rate of permeation than the anions of weak 
acids [26]. Occludins, claudins and tricellulin are prime proteins at the tight junctions , 
which either governs several basic functions like formation of barrier, channels or 
specific tasks like signaling molecules, regulating absorption of certain molecules etc. 
[27]. In place of forming barriers, some proteins from the Caludin family such as claudin-
1 participates in barrier closing while Claudin-2, Claudin-10b and Cluaidin-10 forms 
cation and anion or cation selective channels respectively for paracellular transport [28, 
29]. Transcellular transport is more predominant for the TPPs and relies on molecular 
structure, partition co-efficient and physicochemical properties of the molecule like size, 
lipophilicity, fraction of ionized and unionized species [30]. Most orally approved drugs 
are absorbed passively by the transcellular pathway because of the large surface area of 
the brush border membrane available for absorption, which 1000 times is larger than the 
paracellular surface area [31]. Furthermore, permeability studies in Caco-2 monolayers 
showed lipophilic and higher molecular weight compounds choose transcellular route 
over paracellular transport [32].  
 
The transcellular pathway is different from the paracellular pathway for few 
reasons. Mainly, it can be mediated by either passive diffusion or specific amino acid, 
peptide transporter or endocytosis while paracellular transport takes place via passive 
diffusion only [33]. During transcellular transport, TPPs are first absorbed at the brush 
border apical membrane following a diffusion gradient and then they move through the 
enterocytes to the basolateral membrane where it gets absorbed by facilitated diffusion 
with the help of specific active carrier transport proteins[34]. Figure 2-1 lists all the 
barriers associated with oral delivery of TPPs in G.I.T.  
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Figure 2-1. Key contributors in G.I.T. governing oral delivery of TPPs 
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CHAPTER 3.    STRATEGIES FOR ENHANCING ORAL DELIVERY OF 
PROTEINS AND PEPTIDES 
 
 
Permeation/Absorption Enhancers 
 
To show its therapeutic potency the orally administered TPPs must be absorbed in 
the systemic circulation. However, unfavorable physico-chemical properties result in low 
bioavailability of orally administered TPPs. Co-administration or incorporation of 
permeation enhancers improve bioavailability of TPPs by increasing their cellular 
permeability along the intestinal epithelia. Permeation enhancers modulate several 
functions, namely interacting with the membrane lipid or proteins and thus destroying 
cellular integrity of the tight junctions or opening it, lowering mucus viscosity and 
increasing in membrane fluidity etc. which provide a temporary route to cross intestinal 
epithelia and reach the systemic circulation either via transcellular or paracellular 
pathways [35]. Although, non-selective destruction of the intestinal lipid surface may 
allow the toxins, undesirable pathogens present in the GIT to get absorbed in the systemic 
circulation [36]. Ideally, the intestinal epithelium disruption should be reversible and 
temporary. Tetradecylmaltoside used as permeation enhancer and increased oral 
bioavailability of the enoxaparin by reducing transepithelial electrical resistance in vitro 
in C2BBel cell extracts. Although transepithelial electrical resistance was restored after 
60 minutes of exposure of cells to tetradecylmaltoside [37].  
 
Several chemical classes of these compounds like chelating agents (EDTA, 
EGTA), surfactants (Sodium lauryl sulfate), bile salts (Salicylates, sodium glycocholate), 
fatty acids (Oleic acid, Linoleic acid, Caprylic acid) and theirs salts are widely used as 
permeation enhancers in preclinical development of several TPP formulations. Chelating 
agents forms complexes with Ca2+ ions present in tight junction and dismantles the 
structural organization of tight junctions, which subsequently aids in paracellular 
permeability of the TPPs. Sometimes calcium chelating agents can be toxic because 
calcium depletion can induce significant injury to the cell structure by distorting actin 
filaments, adherent junctions and cell adhesion molecules [19].  
 
Surfactant monomers accumulate at the brush border membrane of the intestinal 
wall and cause acute damage to augment TPP permeation. Wei J. Xia and co-workers 
have found a maximum surface pressure of 25dyne /cm or more is needed to damage the 
biological membrane [38]. A wide range of surfactants including anionic (sodium 
dodecyl sulfate and sodium dioctyl sulfosuccinate) and non-ionic (polysorbate 80 and 
polyoxyl 40) surfactants are used in preclinical development of the TPPs. Anionic 
surfactants are more effective than the non-ionic surfactants in increasing transepithelial 
permeability [39]. Mechanism of medium chain fatty acids as absorption enhancer is not 
well understood in vivo though it is believed that it downregulates tricellulin and claudin-
5 expression which is important to maintain tight junction integrity and solubilizes 
phospholipid bilayer temporarily and reversibly [40]. Sodium caprate, sodium salt of 
medium chain fatty acid capric acid is already a FDA approved food additive also 
investigated as a absorption enhancer for oral delivery of insulin [41] and a GLP-1 
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peptide analog using Gastrointestinal Permeation Enhancing Technology (GIPET™, 
Merrion Pharmaceuticals, Dublin, Ireland) [42]. Orally administered dispersions of 
Insulin with saturated fatty acids e.g. lauric, palmitic and stearic acid as absorption. 
enhancer restored the blood glucose level from 105 to 75mg/dl in rabbit [43].  10mM of 
sodium caprate induces rapid and reversible opening of tight junctions for paracellular 
pathway for intestinal absorption drugs up to 10kDa molecular weight[29].  
 
Zonula occludens toxins (ZOT), produced from the bacteria vibrio cholera 
reversibly increase paracellular absorption of orally administered insulin in rabbit 
intestine by 10 fold via enhancing the permeability through the tight junctions without 
toxicity issues [44]. ZOT is only acts through a specific intestinal receptor reversibly and 
inactive in microflora containing colon, which is susceptible to mucosal damage [45, 46]. 
ϪG, biologically active fragment of ZOT enhances intestinal absorption of drugs 
susceptible to efflux transporters by interacting with PGP [47].  
 
Bile salts are negative charged endogenous surfactant used as potent permeation 
enhancers. They act above or sub critical micellar concentration (CMC) and on both the 
hydrophobic and hydrophilic domain of the biological membrane. They anchor at the 
lipid bilayer of the membrane and form micelles near CMC which leads to elimination of 
the membrane lipid components [48]. Sodium deoxycholate, a commonly used bile salt as 
an absorption enhancer  and increased paracellular absorption of hydrophilic model drugs 
and both transcellular and paracellular absorption of the hydrophobic drugs by reducing 
the transepithelial electrical resistance in Caco-2 cell monolayers [49]. Bile acid salts are 
also used to increase oral bioavailibity of salmon calcitonin and insulin oral formulation 
[50]. Sodium taurodeoxycholate, a secondary bile acid isolated from the intestinal 
primary bile acid successfully improve oral absorption of  epidermal growth factor 
peptide both in vitro Caco-2 and in vivo xenograft model [51, 52].  
 
Last few decades, a wide variety of absorption enhancers have been investigated, 
but most of them are toxic due for causing irreversible and significant damage to the 
gastrointestinal mucosa[53]. However, successful development of permeation enhancers 
depends on three prime factors i) onset of action, ii) degree of permeation enhancement 
and iii) toxicity [54]. See Table 3-1 for commonly used permeation enhancers and their 
mechanism of action. 
 
 
Enzyme Inhibitors 
 
Biological drugs must retain their structural integrity before getting absorbed into 
the systemic circulation to exert their activity. Most orally administered TPPs are 
vulnerable to various proteolytic enzymes while passing through the GIT mainly stomach 
and small intestine. However, co-administering protease inhibitors like pancreatic 
inhibitor, soybean trypsin inhibitor, camostat mesylate and aprotinin increase orally 
administered TPPs bioavailability by reducing presystemic enzymatic degradation by 
trypsin or α-trypsin [74]. Protease inhibitors can be classified structurally as follows i) 
amino acid based and modified inhibitors (N-acetylcysteine), ii) Peptides and modified 
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Table 3-1. Permeation enhancers used in oral TPP formulation 
 
Class  Examples  Mechanism of Action 
Chelating 
agents 
 EDTA, EGTA  Modulates and perturbs structural 
integrity of tight junctions 
Surfactants  Sodium lauryl sulfate, 
Polyoxyethylene ethers, 
Tween 
 Destabilizes both proteins and lipid 
present at membrane and increase 
intercellular space for transportation 
of molecules 
Bile salts  Salicylates, Sodium 
glycocholate,  
 Endogenous surfactant, acts above 
CMC to eliminate membrane lipid 
components 
fatty acids and 
theirs salts 
 Oleic acid, Linoleic acid, 
Caprylic acid 
 Disintegrates the tight junctions and 
solubilizes phospholipid bilayers 
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peptides as protease inhibitor (bacitracin, cyclic dodecapeptide), iii) Polypeptide protease 
inhibitors (aprotinin), iv) non-amino acid based protease inhibitor (disisopropyl 
fluorophosphates, phenylmethylsulfonyl fluoride) [55]. Appropriate choice of enzymatic 
inhibitor depends on the location of the target enzyme and cellular distribution. So, they 
are further divided based on their location such as i) inhibitors of luminally secreted 
proteases (aprotinin) and ii) Inhibitors of membrane bound proteases (amastatin, bestatin) 
[55]. Non-amino acid-based inhibitors like disisopropyl fluorophosphates, 
phenylmethylsulfonyl fluorides downregulate serine proteases. Although they also inhibit 
acetyl cholinesterase, which makes them toxic and unacceptable for pharmaceutical use 
[55]. FK-448 is low toxic, non-amino acid based inhibitor of chymotrypsin which helped 
in increasing intestinal absorption of insulin in rats and dogs [56].  
 
Other types of protease inhibitors e.g. chymostatin, aprotinin, Bowman-Birk 
inhibitor and aprotinin showed to increase bioavailability of orally administered Insulin 
microsphere formulation by preventing degradation via digestive enzymes like pepsin, 
trypsin and α-chymotrypsin [57]. High molecular weight of the polypetide protease 
inhibitors like aprotinin allowed them to be efficiently formulated in the sustained release 
oral dosage forms such as insulin loaded poly(vinyl alcohol)-gel spheres [58]. Aprotinin 
is one of the pioneering enzyme inhibitors used in several oral TPP formulations because 
of its inhibitory action on trypsin and chymotrypsin [59].  
 
There are few models to evaluate protective effects of these inhibitors. One of 
such tests for luminally-secreted protease activity is to incubate the TPP delivery system 
with the protease inhibitor in gastric or intestinal fluid at 37°C and then estimating 
percentage of residual drug in the medium [60]. For in vivo protease inhibitory studies, 
insulin is used as a model drug as it is degraded by both luminal and brush border 
proteases [57, 61]. Enzymatic inhibitors have significantly contributed to enhance 
bioavailability of orally administered TPPs. Although sometimes their acute and 
irreversible activity can lead to inactivation or over activation of certain enzyme-activity 
which can cause severe side effects like unstable digestion of nutrition, hypertrophy and 
hyperplasia of pancreas etc. [62]. 
 
 
Structural Modifications 
 
The purpose of structural modifications of TPPs is to improve resistance to 
proteolytic degradation, immunogenicity, improve membrane penetration or stability. It 
can be done in two ways. The first approach is modification of the accessible side chain 
amino acid groups. Another method is targeting carbohydrate groups of glycoproteins 
[63]. Permeation of peptides were enhanced by conjugating lipophilic molecules like 
fatty acids to peptides to increase the hydrophobicity of peptides. For example, two 
palmitic acid derivatives of insulin monopalmitoyl- and dipalmitoyl-insulin were 
synthesized. These derivatives were more effective as indicated by hypoglycemic effects 
in rats and less immunogenic than the native insulin [64]. GIT stability and permeation 
across the intestine was notably increased by chemical modification of thyrotropin-
releasing hormone with lauric acid at the N-terminal pyroglutamyl group. Lauric acid 
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conjugated thyrotropin-releasing hormone was stable in intestinal mucosa and efficiently 
up taken by the brush mucosa where it was converted into its native form [65]. Another 
approach is introduction of protective groups that prevent enzymatic degradation. A 
derivative of insulin with introduction of α-lipoic acid offered excellent protection against 
the proteolytic enzyme trypsin. Lipoic acid has a disulphide bridge which acts a natural 
antioxidant [66]. Similarly introduction of  ethoxycarbonylmethionine groups for 
protecting glycine and lysine amino groups kept the insulin intact even after 5 cycles of 
degradation [67].  
 
Desmopressin is the synthetic and modified form of naturally occurring anti-
diuretic hormone vasopressin with few structural modifications. N-terminal amino acid of 
desmopressin was deaminated and levo-arginine at the 8th position of C-terminal was 
replaced with dextro-arginine. These changes enhanced passive transport of the 
desmopressin when compared to vasopressin through the intestinal epithelia possibly 
because of protection from the proteolytic degradation [68]. Another method is 
cyclization, which increases half-life of the TPPS by protecting them from degradation 
by the exo and endopeptidases present in the blood. Typically, proteolytic enzymes favor 
flexible structures as their substrate. However cyclization rigidifies conformations of 
peptides and proteins which decreases the susceptibility of enzymatic degradation  [69]. 
 
 
PEGlyation 
 
Most of the TPPs suffer from their short biological life due to rapid clearance and 
inherent low stability due to proteolytic enzymes in systemic circulation. However, these 
shortcomings of the TPPs can be overcome by covalent binding of a biocompatible 
polymer to shield it from enzymatic degradation and improved properties like low 
immunogenicity, enhanced bioavailability and pharmacokinetic profile. A handful of 
polymers such as PHPMA, POEGMA, PNIPAM, PLGA, PDEAM, PEG used for oral 
delivery of TPPs. PEG has become the most widely studied among them due to several 
advantages like biocompatibility, less toxicity, improved biological and circulation half-
life and low cost compared other polymers of the same molecular weight available [70]. 
PEG is amphipathic in nature soluble in both polar and non-polar solvents [71]. PEG can 
be derivatized with a functional group, which will allow chemical conjugation with 
reactive amino acids of protein or peptides. This process is known as PEGylation [72]. 
PEGylation protects the structural integrity of TPPs by shielding them from proteolytic 
enzymes before absorption. Thus, PEGylation increases the duration of action of TPPs in 
human body. Another important aspect of PEGylation is to decrease immunogenicity. 
PEG layer safeguards TPPs from the rapid and intense immune reaction when recognized 
by antibodies, B cells. α-momorcharin (α-MMC), a type I ribosome-inactivating protein 
when PEGylated showed less immunogenicity and immunotoxicity in vivo [73]. 
Conjugation of PEG increases the size of small peptides so that they are less readily 
excreted by glomerular filtration [62]. Abuchowski and coworkers first reported of 
superior properties of BSA-PEG conjugates than the alone BSA [74]. Since then FDA 
has approved a handful of parental PEG-modified TPP formulations and several of them 
are investigated in clinical trial [75]. Their successfulness in oral delivery is reported 
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though limited when compared to the parental dosage forms. Jensen-Pippo KE and co-
workers reported recombinant human granulocyte colony stimulating factor-PEG 
complex effective orally by increasing stability and retention in vivo [76].  
 
An insulin-PEG delivery system with a thoiolated polymer poly(acrylic acid)–
cysteine carrier matrix was more stable in vitro and effective in redcuing blood glucose 
levels in diabetic mice when administered orally than the native insulin [77]. Hexyl-
insulin monoconjugate or HIM2 is an orally delivered human insulin modified with a 
small PEG and permeation enhancer at the Lys-β29 residue via an amide bond. Oral 
single administration of HIM2 (0.75mg/kg) increased whole-body glucose disposal and 
inhibited endogenous glucose production in healthy nondiabetic human subjects in a dose 
dependent manner [78]. HIM2 was also found to be effective in type1 and 2 diabetic 
subjects [79, 80]. NOBEX Corporation and BIOCON have jointly developed HIM2 and it 
is approved as Insugen in India [81]. 
 
 
Mucoadhesive Polymeric Systems 
 
Mucoadhesive polymers such as hydroxyl propyl methyl cellulose, chitosan, 
carbopol provide an excellent platform for oral delivery of TPPs. The process of adhesion 
of these polymers to the mucosal tissue in GIT is known as muco-adhesion. Muco-
adhesion enhances degree of drug absorption by extending the residence time of the drug 
carriers at the absorption site and providing higher drug concentration to absorption site. 
Hydrophilicity and high molecular weight of the mucoadhesive polymers help in 
enhancing solubility of poorly absorbed peptide and proteins while protecting them from 
enzymatic degradation in GIT [82]. A chitosan-coated nanosphere with elcatonin 
significantly enhanced the physiological effect that is reduction in blood calcium level 
when compared to the uncoated nanosphere and elcatonin solution in rat [83]. N‐
trimethyl chitosan chloride, partially quaternized derivative of chitosan showed enhanced 
absorption than the normal chitosan salts in neutral and basic conditions [84]. Polymer 
properties dramatically change in respect to change in the environment pH, temperature, 
ionic strength or presence of certain enzymes. For examples, PAA (poly acrylic acid) or 
PMA (poly methacrylic acid) hydrogels with azoaromatic crosslinkers are developed for 
colon-targeted delivery of macromolecules. Swelling of these polymers occurs only with 
an increase in pH and highest in neutral pH of colon. However, azoreductase, produced 
by the microbial flora of the colon can degrade azoaromatic linkers [85]. Another 
example of stimuli-sensitive mucoadhesive polymeric system is insulin loaded 
microparticles (100 –150 μM) constituted of PMA and polyethylene glycol (PEG) 
crosslinked P(MAA-g-EG)) polymer network. P(MAA-g-EG)) polymer network inhibits 
calcium dependent proteolytic enzymes such as trypsin [86].  
 
Furthermore, insulin is protected in the acidic environment of the stomach as the 
polymer network only swells and releases the cargo in the neutral and basic environment 
of the intestine. PEG molecules provide adhesive properties for this formulation by 
penetrating into the mucosa [87]. Orally administered insulin loaded microparticles 
showed good pharmacokinetic properties and hypoglycemic effect both in healthly and 
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diabetic rats and these effects last up to 8 hrs following administration [87]. Incorporating 
a biocompatible endogenous permeation enhancer such as spermine, spermidine 
improved bioavailability of calcitonin-loaded mucoadhesive PAA nanoparticles. 
Spermine incorporated nanoparticles showed significant and prolonged reduction in 
blood calcium level when given orally in rats. This polyectrolyte nanoparticle complex 
were made from the interaction of the carboxylate groups of the PAA and magnesium 
ions or the amino acid groups of the spermine [88].  
 
Another mention worthy mucoadhesive delivery system is GI-MAPS developed 
for oral administering of TPPs. GI-MAPS has four distinct layer serving different 
purposes contained in an enteric molecule. The backing layer is formulated with a water-
insoluble polymer ethyl cellulose which gives protection from proteolytic enzymes. Then 
comes the surface layer which is coated an adhesive layer and made up of an enteric pH-
sensitive polymer like hydroxypropylmethylcellulose phthalate (HP-55®), Eudragit 
L100® or S100®. The middle portion containing the drug and pharmaceutical excipients 
like organic acid (citric acid), polyoxyethylated castor oil derivative (HCP-60®) is made 
of cellulose, which is conjugated to the ethyl cellulose by heating press method. The 
surface layer was connected to the middle layer by an adhesive carboxyvinyl polymer 
(Hiviswako® 103). This unique system was studied to deliver a protein recombinant 
human granulocyte colony-stimulating factor (G-CSF) orally in beagle dogs and the 
pharmacological effect (increase in tota white blood cells count) was increased by 1.3 
folds [89]. Thiolated mucoadhesive polymers have superior mucoadhesive properties 
than then conventional ones as thiol groups help in forming strong covalent disulfide 
bonds with the cysteine groups of mucous glycoproteins. Mucoadhesive properties of 
these polymers increase with the increase in thiol groups present. They also renders 
enzymatic protection [90]. Thiolated chitosan polymers exhibited 3 fold higher 
permeation rate when studied using passive diffusion marker rhodamine 123 compared to 
the unmodified chitosan [91].  
 
High MW thiomers have better mucoadhesive characteristics due to significant 
entanglement with the mucus glycoproteins caused by long chain polymer but the suffer 
from deficient mobility and penetration across the mucus layer [92]. However, short 
chain low MW thiomers show higher penetration and mobility but negligible 
entanglements [93]. Combing both of the thiomers have resulted in better gelling and 
mucoadhesive properties [94]. Although mucoadhesive polymer showed improved 
absorption properties but their application is limited because of the mucus turnover 
process that takes place in every 12-24h in the human intestine [95]. 
 
 
Cell Penetrating Peptides 
 
Early research has showed the drawbacks and challenges related to the therapeutic 
activity of oral delivered TPPs. Hydrophilic nature of peptides and proteins makes it 
difficult to cross the lipophilic epithelial membranes, thus resulting in low bioavailability 
and absorption [96, 97]. For improving oral delivery of TPP based formulation, cell-
penetrating peptides (CPP) are introduced. These CPPs are the protein transduction 
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domain made up of 3-30 protein residues. The hydrophilic and hydrophobic parts of 
CPPs facilitate the internalization and conjugation of various entities such as liposomes, 
nanoparticles to the targeted sites [98]. The mode of membrane permeation by CPPs 
depends on the following factors such as sequence, the concentration of CPP, incubation 
volume and the reaction involved in the preparation of CPP attached to the protein cargo 
[99]. CPPs are used as vehicles for conjugating desired TPPs by covalent conjugation or 
physical complexation. Covalent conjugation between CPP vector and its cargo protein 
occurs due to disulfide bonds, amide bonds, or by using specific linkers [99, 100]. 
Physical complexation within vector CPP and cargo TPP source occurs by electrostatic or 
hydrophobic interaction, which is obtained by mixing vector and protein at a maintained 
CPP concentration [101, 102]. Physical complexation can also occur between CPPs and 
hydrophilic protein using amphiphilic linkers. The most frequently used CPPs are 
primarily obtained from the transcriptional activator protein present in the HIV-1 virus.  
 
CPPs are basically peptides with a high concentration of basic amino acids. The 
commonly used peptides are model amphipathic peptide (MAP), transportan, and 
antennapedia [103, 104]. CPPs may follow two paths for delivering TPPs at the targeted 
site. First, by direct penetration, which involves disturbance and distortion of lipid bilayer 
membrane leading to the availability of a molecule at the cytoplasmic site. Second, by 
endocytosis. These paths help in enhancing the permeability and bioavailability of 
proteins [105]. In natural conditions, it is impossible for the proteins to trigger therapeutic 
activity against different organelles or the cell nucleus by itself, due to reduced 
membrane permeability [106]. Hence, the functional groups present in CPPs facilitate the 
therapeutic protein within the cytoplasm to trigger such therapeutic activity. As proteins 
are one of the gold standards for nonimmunogenic therapy for treatments, CPPs play a 
prime role as a vector for enhancing protein delivery. Previous works by Dowdy and 
group showed that the use of the HIV-TAT CPP vector has successfully enhanced the 
uptake of high molecular weight protein beta-galactosidase (120 kDa) across the blood-
brain barrier, which has been previously failed to be delivered majorly due to its large 
size and physiochemical property [107].  
 
Being small sequence protein, CPPs with peptide bonds are vulnerable towards 
environmental changes that make their stability and use quite challenging and limited 
[108]. From the findings of Verdurmen and others on cationic CPPs of L and D amino 
acids, it is observed that the D form of amino acid showed a decreased uptake in MC57 
fibrosarcoma and HeLa cells, which affects the overall uptake of CPP. Thus 
stereochemistry of the CPPs might be explored for efficient cellular targeting [109]. 
Changing amino acid stereochemistry or by modifying amino acid groups at specific 
sequences to avoid excess cleavage caused by proteases uptake of TPPs can be enhanced. 
In a CPP made up of human calcitonin, N-methyl-phenylalanine has substituted the D-
phenylalanine group at a specified position of the protein, which has decreased the 
degradation of CPP without altering its penetration property when targeting HEK 293T 
cells [110].  
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Besides being vulnerable to proteolytic enzymes, the high molecular weight and 
low solubility of proteins make its delivery through the oral route difficult. Ganguly and 
group have done extensive work with naked (one which has no CPP attached group) 
125I-labeled Polyamine Nucleic Acid TransActivation Response (PNATAR) and the 
CPP conjugates namely, 125I-labeled PNATAR-penetratin and 125I-labeled PNATAR-
TAT. Studies on Balb/C mice showed a proper distribution and retention of the CPP 
conjugated radio-labeled protein within the organs. Radioactive labeled CPP conjugated 
protein showed rapid clearance from different organs, but a significant amount of the 
protein showed a controlled release for an extended period. Although the control 125I-
labeled PNATAR group showed similar distribution and clearance profile as that of the 
CPP conjugated PNATAR groups in Balb/C mice, its uptake was quite lower than the 
CPP conjugated groups [111]. Polyamine Nucleic Acids (PNAs) are the recently used 
DNA mimics used as a potent antiviral agent that lack the phosphate sugar backbone. The 
PNAs are protected against the catalytic degradation caused by proteolytic enzymes 
[112]. PNAs target and inhibit the Trans Activation Response (TAR) element of the viral 
genome. Combining CPPs such as penetratin and TAT with PNAs improves delivery of 
PNAs because CPPs enhance the affinity of the PNA complex for the TAT region of the 
virus [113]. 
 
 
Enteric Coating for Oral Delivery of Peptides 
 
TPPs are absorbed in the small intestine where the pH is higher than stomach and 
pancreas. They are highly sensitive towards enzymatic degradation, which requires 
special protection from the gastric and pancreatic enzymes. For protecting TPPs from 
degradation, pH sensitive polymers are used as enteric coating. These polymers protect 
proteins from low stomach pH and accelerates its release at absorption site of small 
intestine. For example, oral delivery of insulin require such polymer to enable site-
specific release while passing down the GIT [36]. Currently the  preferred way of 
delivering insulin is  parenteral route of administration but, being a protein produced 
naturally by pancreas, it is susceptible towards degradation from proteolytic enzymes 
when it passes down the GIT [114]. For enhancing and controlling the pH specific oral 
delivery of insulin within the GIT, Touitou et al designed oral delivery platform for 
insulin. Gelatin capsules were used for encapsulating insulin where these capsules were 
enterically coated with different ratio of polyacrylic polymer (Eudragit RS, L and S) to 
facilitate pH dependent insulin release. In vivo studies in rat showed maximum insulin 
release at pH 7.5 and 8 from the formulation containing Eudragit RS1 and RS2 
respectively. Hypoglycemic studies by measuring blood glucose concentration of rats 
showed significant level of hypoglycemia obtained from both the formulation when 
compared to control group [115].  
 
Another pH sensitive polymer which has been used for successful oral delivery of 
insulin is Methacrylic acid copolymer. This polymer can serve as a protection for insulin 
from enteric and pancreatic peptidases and also allow synthesis in a commercial scale 
[116]. Gwinup and co-workers utilized the previous work done by Schroender et al. and 
used of Methacrylic acid copolymer encapsulated 5-amino-salicylic acid formulation for 
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treating ulcerative colitis. Methacrylic acid copolymers are soluble in  pH above 7 and 
are itself non-toxic in nature [117, 118]. pH sensitivity of methacrylic acid encapsulated 
insulin showed its partial release in the colon and complete dissolution of polymer in the 
duodenum. X ray studies on formulation showed intact drug profile within the capsule 
until it reaches cecum region. Advantage of oral administration of insulin was observed 
over its parenteral administration by noticing that blood glucose level didn’t decrease 
immediately after oral administration thereby avoiding the occurrence of immediate 
dramatic hypoglycemia which is observed after insulin injection [119].  
 
There are few disadvantages associated with enteric coating of TPPs. Enteric 
coating enhances the bioactivity of encapsulated TPPs but does not play any role in 
enhancing the process of absorption. To minimize these drawbacks, in addition to the 
protein component, protease inhibitors and membrane permeability enhancers can be 
added which can enhance the overall efficacy of enterically coated TPP formulations 
[120]. Different sites of intestine have different pH, microspheres are designed respective 
to the pH requirement of TPPs to be released throughout the intestine. It has been 
previously reported that for the absorption of insulin, an optimal region of small intestine 
is required. Mid-jejunum region of the small intestine is the most preferred site for insulin 
absorption which protects it from gastric and pancreatic enzyme [121]. Small intestine 
has a variation of pH range which going for upper to lower part of it therefore, for 
achieving an effective release of insulin throughout the intestine, different ratio of 
Eudragit has been used in a formulation made by Morishita and his group. Formulation 
was made using Eudragit L100 (L) alone which make the formulation sensitive towards 
pH 6. This facilitates drug release in upper intestinal region. This enteric formulation was 
further modified with adding 1 part of Eudragit S100 and 1 part Eudragit L100 and it is 
soluble at pH 7 and above. This modification enhanced pH specificity of formulation 
throughout small intestine [122]. 
 
 
Liposomes 
 
Recent days lipid-based carrier systems are widely studied to deliver proteins 
orally and in different stages of clinical development.  However, conventional liposomal 
systems have not met with mention worthy success because of their inefficiency to 
encapsulate hydrophilic peptides and proteins. They also suffer from instability in GIT 
and poor permeation through the mucosa to reach the epithelial layer. However, these 
instabilities can be countered significantly via surface modifying the liposome with 
musoadhesive polymer like chitosan and protease inhibitors like aprotinin or the Bowman 
Birk Inhibitor. When calcitonin was delivered using this unique mucoadhesive polymer 
chitosan and protease inhibitor approtinin conjugate in rats, the area above the blood 
calcium concentration–time curve was increased 15fold compared to the calcitonin 
solution [123].  
 
Another surface modified mucoadhesive polymer based on liposome formulation 
is carbopol-lectin liposome conjugate. Lection, isolated from the Triticum vulgaris is a 
non-toxic glycoprotein which binds to N-acetyl-D-glucosamine sugar present in the 
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intestinal mucus membrane [124]. Calcitonin loaded carbopol-lectin liposome conjugates 
were conjugated covalently via carbodiimide method and had better pharmacokinetic 
properties and pharmacological effect in vivo in compared to carbopol-calcitonin 
liposomes [125]. Silica coating on the liposomes also helped in preventing proeteolytic 
degradation of the encapsulated drug and increase encapsulation efficiency [126]. 
Fusogenic liposomes are made by fusing Sendai virus envelop glycoprotein, which helps 
in internalizing into the cytoplasm, by membrane fusion. Fusogenic liposomes 
encapsulated insulins showed enhance insulin absorption exhibited by a rise in 
hypoglycemic effect with very little mucosal damage [127].  
 
Liposomes can be also be surface modified for site specifically delivery. For 
example, Liposomes made of distearoylphosphatidylcholine, phosphatidylserine, and 
cholesterol were selectively more by the peyer patches of the lower ileum [128]. First 
generation liposomes also suffered from low circulation systemic half-life. However, 
modifying surface of liposomes with PEG increased their circulation lifetime by 
protecting from the opsonization and capture by RES [129]. Polymerosomes are modified 
forms of liposomes with hydrophilic and hydrophobic block polymer with PEG as their 
hydrophilic block [128]. Polymerosomes have more mechanical stability and hydrophilic 
interior to incorporate more hydrophilic peptides and proteins. Although reported that 
they suffer from poor encapsulation efficiency as low as 5% [130]. Another interesting 
study was double liposomes, which had an inner core of smaller liposome of size around 
100nm within the larger liposome. Four different types of inner liposomes (neutral, 
cationic, VET and cationic-VET) were prepared by either Coatsome® or 
mechanochemical method. Then the double liposomes were prepared by a combination of 
mechanochemical and glass-beads method. The hypoglycemic effect of the double 
liposomes with cationic charged core was better in the diabetic rats when administered 
orally. This is due to ability of the double liposomes to protect its cargo from enzymatic 
degradation and ability of the positively charged inner liposome to enhance intestinal 
absorption. This study emphasized the role of surface charge of the particles in intestinal 
absorption [131].  
 
Hybrid silica nanoparticle coated liposomes were synthesized to counter physical 
instabilities of liposomes like vesicle aggregation, fusion and creaming during 
manufacturing and storage. Silica layer provides a strong protection at the liquid liquid 
interface and also enhances in vivo absorption [126]. Achaeosomes, engineered 
liposomes made with membrane lipid isolated from Sulfolobus acidocaldarius are 
superior to the traditional liposomes in lowering blood glucose levels when administered 
orally with insulin incorporated. Archaeobacterial lipids provide protection from extreme 
pH, oxidation, action of bile salts and lipase [132]. 
 
 
Microspheres 
 
Polymeric microspheres of certain size range (1-1000μM) can be an excellent 
alternative option for controlled oral delivery of peptide and proteins. They can be 
prepared by various techniques such as spray drying, solvent evaporation, phase 
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separation-coacervation [133]. Drug can be released from them following several ways 
like polymer degradation/erosion or diffusion [134]. Polymeric microspheres have widely 
used in several oral vaccine preparation. For instance, Vibrio cholerae whole cell oral 
microsphere vaccine was formulated based on PLGA by double emulsification method 
with a high encapsulation efficiency up to 95%. Japanese encephalitis virus vaccine was 
also prepared by encapsulating in a biodegradable PLGA based microsphere made by 
W/O/W solvent evaporation method [135].  
 
Another orally administered PLGA microsphere of lactoglobulin was prepared by 
W/O/W method to treat newborns prone to allergies to milk proteins. Tween 20 was 
added in this formulation, which increased protein encapsulation efficiency and superior 
controlled release [136]. However, proteins suffered from instabilities when encapsulated 
in PLGA microspheres by w/o/w method. Proteins are surface active, and they have 
tendencies to be adsorbed at the water/organic interface, which can lead to aggregation 
and unfolding of their structure. Although these issues can be regarded by S/O/W or 
S/O/O method of encapsulation. This is because proteins are stable and rigid in the 
organic phase. There unfolding or structural modification does not take place [137]. 
Insulin loaded microparticles were fabricated from blends of  PEG with poly (L-lactide) 
(PLA) homopolymer and poly (DL-lactide co-glycolide) copolymers by water-in-oil 
solvent extraction method which showed a really high encapsulation efficiency up to 56% 
[138].  
 
Biologically erodible microsphere formulation with polyanhydride copolymers of 
fumaric and sebacic acid, poly (FA:SA) demonstrated better adhesive properties than the 
microsphere made of other polymers. They can also penetrate through the intestinal 
epithelium as well as follicle-associated epithelium covering the lymphoid tissue of 
Peyer's patches [139]. pH-sensitive microspheres were synthesized based on chemically 
modified soybean hydrolysate with aromatic acyl chlorides. These low-cost microspheres 
were stable pH<3.5 and soluble at pH>5.0. Oral delivery of salmon calcitonin or porcine 
insulin using these microspheres resulted into higher bioavailability [140]. Recently, 
using membrane emulsification technique combining Ca2+ ion and chitosan polymer 
solidification alginate-chitosan insulin microspheres were synthesized with excellent 
loading efficiency (56%) and activity maintenance (99.4%). These microspheres showed 
remarkable stability in stimulated gastric fluid and reduced blood glucose level 
successfully in diabetic rats for long time until ~60h [141]. 
 
 
Microparticles/Nanoparticles 
 
Nanoparticles or microparticles of certain size ranges (10-200nm) are expected to 
penetrate through the mucus pores to reach the blood stream crossing the epithelial 
membrane. However, larger nanoparticles (200nm or 500nm) are also found to be 
effectively diffusing through the mucus layers if they are surface modified with PEG 
[142]. Nanoparticle absorption through GIT is governed by nature of its components, size 
and surface charge. Nanoparticle delivery systems have several advantages such as: i) 
protection from severe environment and proteolytic enzymes in GIT, ii) slow, controlled 
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and site specific delivery of the cargo, iii) ability to cross the mucus membrane due to 
smaller size, iv) high volume and surface area for interaction with mucus and epithelial 
lining at GIT, v) allowing administration through non parenteral routes like oral route 
with improved bioavailability and pharmacokinetics properties etc. [105, 143-145]. A 
handful of polymers like alginate, chitosan, cyclodextrins, PLGA are used to manufacture 
nanoparticles for oral administering of TPPs.  
 
Polymers can be further modified by grafting or substituting with functional 
groups that can used for targeting specific tissues or opening tight junction or 
mucoadhesion or permeation enhancing etc. [146]. In a recent study, alginate-chitosan 
nanoparticles were made by ionotropic pre-gelation method for oral delivery of insulin. 
This polyelectrolyte complexs were synthesized by coating alginate (anionic 
polysaccharide) containing insulin core with chitosan (cationic deacetylated form of 
chitin) by polyelectrolyte complexation method. FITC-insulin containing nanoparticles 
showed uptake on both the surface of the intestinal enterocytes and M-cells of the Peyer’s 
patches. Also oral administration of these nanoparticles significantly reduced blood 
glucose levels in diabetic rats up to 59% and 55% when given dose of 50 and 100 IU/kg 
respectively [147].  
 
Additionally, nanoparticles were engineered for site-specific uptake of the cargo 
by mononuclear phagocytic system to reduce off-target effects. It can be achieved by 
coating the surface of the by blood proteins for off opsonization. One of the 
disadvantages of this kind of delivery system is liver toxicity as most of the nanoparticle 
end up in liver for further purification. However, hydrophilic coating of the nanoparticles 
can reduce opsonization and uptake by mononuclear phagocytic system. [148]. 
Nanoparticle surface was also modified with ligands like VB12, lectins, biotins or folic 
acid to facilitate pronounced uptake by receptor mediated endocytosis [149]. See Table 
3-2 for currently available strategies for improving oral bioavailability of TPPs 
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Table 3-2. Strategies for improving oral bioavailability of TPPs 
 
Strategies Results 
Permeation/Absorption 
Enhancers 
Increased permeability through the intestinal 
epithelia. 
Enzyme inhibitors Protection from acidic environment and proteolytic 
enzymes in G.I.T. 
Structural modifications Increased permeability, solubility and resistance to 
proteolytic degradation 
PEGlyation Protection from proteolytic enzymes, low 
immunogenicity, enhanced bioavailability and 
pharmacokinetic profile 
Cell penetrating peptides Enhanced permeation and site-specific delivery of the 
TPPs 
Mucoadhesive polymeric 
systems 
Penetration through highly viscous mucus layer, 
enzymatic protection, Site specific delivery 
Microspheres, Nanoparticles 
and Liposomes 
Improved bioavailability, pharmacokinetics, physical 
stability, epithelial permeation and enzymatic 
protection 
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CHAPTER 4.    CLINICAL INVESTIGATION OF ORAL PEPTIDES AND 
PROTEINS 
 
 
Oral delivery of TPPs is an excellent alternative to the current painful parenteral 
delivery. There is a continuous effort both in academia and industry to develop TPPs. 
However only few of them have got clinical approval. Here we have put few pivotal TPP 
formulation which are currently under different phases of clinical trials. 
 
 
Eligen® by Emisphere 
 
Eligen is a delivery agent which has been developed by Emisphere technologies. 
This company uses sodium N-[8-(2-hydroxy benzoyl) aminocaprylate] as a carrier 
molecule for attaching drug through weak non-covalent association. The integrity of drug 
remains unchanged when conjugated with the carrier molecule and can be delivered 
across the epithelial membrane.  SNAC enhanced insulin absorption by 10-fold 
transcellularly without damaging the tight jucntions significantly. It also helps in 
maintain GIT stability by protection from proteolytic enzymes. Oral insulin and regular 
insulin have been used with SNAC for treating type 2 Diabetes. It has completed its 
phase I trial (NCT00982254) [150]. Currently it is phase II clinical trial [151]. 
 
 
CLEC by Altus Pharmaceuticals 
 
Crystallization of bulk protein is one of the methods to achieve purified proteins 
when required in bulk form. Produced protein crystals have stability much greater than its 
amorphous state therefore, this provides an additional advantage of crystallization. 
Protein crystallization generally involves the step of batch crystallization caused by 
crosslinking microcrystals with glutaraldehyde. These crosslinked enzyme crystals are 
known as CLEC are produced by Altus pharmaceuticals, which gives enzymes like 
polypeptides, lipases, esterase, and calcitonin enhanced stability. The produced products 
are stable against self and proteolytic digestion [152]. Commercially available 
TheraCLECTM-protease along with TheraCLECTM-lipase are extensively used as 
pancreatic enzymes products and adjuvant therapy in autoimmune and infectious disease. 
 
 
BioOral by BioSante Pharmaceuticals 
 
Size and surface area of nanoparticles makes it a great vehicle for delivering 
proteins to site-specific areas. Nanoparticle act as one of the standard delivery vehicle 
because of its property of being nonimmunogenic, biodegradable, easy to modify, easy to 
metabolize ad stability during storage [153]. BioOral system has been developed as 
calcium phosphate-based nanoparticles for facilitating vaccine delivery known as 
BioSante. Oral delivery of insulin has been formulated as CAP-PEG-Insulin-Casein 
(CAPIC) where casein encapsulate the insulin-PEG formulation thereby act as an enteric 
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coat to protect insulin from stomach pH. It is available in the market from BioSante 
Pharmaceuticals. It can be used as Ornithine decarboxylase stimulant, Phosphokinase 
stimulants, and protein tyrosine kinase stimulant [154]. 
 
 
Oral-LynTM by Generex 
 
Oral-LynTM is another formulation used commercially for insulin delivery as 
aerosols. Generex biotechnologies have been developing this formulation using a 
minimum amount of excipient. Excipients used for formulating Oral-lyn are 
nonchlorofluorocarbon based propellent and stabilizing agents which protects the 
aerosolized protein formulation from denaturation. Insulin is converted into its micelle 
form with a size greater than 7 µm which is too large to enter the lungs. RapidMist is a 
device profoundly used by people suffering from asthma, is also being used for delivering 
Oral-lyn directly into the oral cavity from which it penetrates down the buccal cavity and 
reaches the blood vessels. Clinical data shows that Oral-Lyn in its Phase III has been used 
for treating Diabetes Mellitus (NCT00668850) [81, 155]. Generex has been marketing 
the same product in India under the name of Oral Recosulin [156] 
 
 
HIM2 by Nobex and Biocon 
 
Hydrophilic proteins and peptides are difficult to deliver through oral route. 
Nobex and Biocon together are trying to address this limitation on a commercial scale by 
introducing lipophilic moiety into the protein structure. Hydrophobic nature of the protein 
would help in increasing its ability to cross the epithelial membrane. Companies have 
designed hexyl-insulin monoconjugate(HIM2), it is a modified form of insulin where 
amphiphilic oligomers conjugate with a primary amine group of the Lys-29 residue found 
in the beta chain of human insulin [80, 157]. It is modified form of insulin, resistant to 
enzymatic degradation and improves insulin absorption when it is administered orally. 
Ongoing studies on HIM2 shows its use as a glucose stabilizer in type 1 Diabetes 
Mellitus [157]. 
 
 
OraldelTM (ANL010) by Apollo Life Sciences 
 
Although enteric coating has shown successful delivery of insulin, proteolysis and 
absorption at intestinal enterocytes limit its commercial use [158]. To enhance the 
delivery of insulin, use of vitamin B12 has met with some success. Vitamin B12 when 
given in form of a dietary supplement, binds to the hepatocorrin salivary enzyme which 
stimulates the transport and absorption of vitamin B12 into the small intestine. Vitamin 
B12 binds further to the intrinsic factor and proceeds down to bind with the intrinsic 
factor receptor present in the wall of the ileum. These processes lead to the endocytosis of 
vitamin B12 and releasing it into the blood serum where it binds to transcobalamin (II). 
This conjugation of vitamin B12 eliminated major drawback associated with insulin 
delivery thereby causing internalization and transport of insulin in blood serum [159, 
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160]. To enhance insulin delivery, Apollo life science has utilized the benefits of using 
Vitamin B12 for preparing sugar nanoparticle-based insulin coated with Vitamin B12 
molecule. The formulation is termed as OraldelTM. In this formulation, insulin was 
encapsulated in the matrix of the nanoparticle. The company assures that this delivery 
system encapsulates 100% of the insulin in the matrix, therefore, can actively normalize 
blood glucose level, when delivered orally [98]. 
 
 
AI-401 by Eli-Lilly and Autoimmune Inc. 
 
Use of recombinant technology is another approach for designing protein 
therapeutics which can be delivered orally. AI-401 is a recombinant insulin formulation 
which has been developed by Eli-Lilly. The company utilizes oral tolerance therapy for 
designing and developing AI-401. Oral tolerance therapy causes suppression of the 
immune response against an antigen [161]. Autoimmune Inc. together with Eli-lily has 
developed AI-401 to suppress the autoreactive T cells. Phase II clinical trial on this 
therapy has shown the normal working of endogenous insulin by delaying the destruction 
of Beta cells present in the pancreas. Clinical studies have successfully completed in 
patients suffering from Type I diabetes [162]. 
 
 
Orasome by Endorex Corporation 
 
Liposomes are vehicles for delivery of therapeutics because of its resemblance to 
the cell membrane. They show excellent drug entrapment ability, biocompatibility, and 
safety. Liposomes are generally used for parenteral drug delivery because of its limitation 
towards oral delivery, caused generally because of its instability in the gastrointestinal 
tract and poor permeability for lipid membrane. Use of ligands and polymers have been 
attained to decrease the limitation associated with oral delivery using liposome [163]. 
Orasome, a polymer-based liposome has been designed by Endorex Corporation, which 
serves a purpose to protect insulin and human growth factor from the acidic stomach pH 
and releasing it into the small intestine. Orasome also helps in protecting the protein from 
low pH and bile salts [164]. 
 
 
GIPET® by Merrion Pharma and Novo Nordisk 
 
GIPET® is another oral delivery technology used for enhancing protein absorption 
by as much as 200 times. This delivers oral therapeutics such as Insulin and GLP-1. 
GIPET is currently used in tablet form of insulin with three different coating and being 
studied for the treatment of Diabetes mellitus (NCT01931137) [165, 166]. 
  
 23 
Oramed by Oramed Pharmaceuticals 
 
Like GIPET, Oramed is also a carrier system used for delivering GLP-1 and 
Insulin. It is under phase II clinical trial when used for insulin delivery and phase I trial 
when used for GLP-I delivery. (NCT02535715) [167, 168]. Ormade’s oral insulin is 
currently investigated for both type1 and type2 diabetes. 
 
 
PeptelligenceTM from Unigene Laboratories, Enteris Biopharma 
 
It is an enteric coated tablet formulation which increases solubility and 
absorptions of peptides. This formulation has two mail components. First a surfactant 
permeation enhancer which loosens the tight junctions and potentiates paracellular 
transport. It also works as excellent solubilizing agent. Another agent is a multifunctional 
pH-lowering component citric acid, which increases absorptive flux. It furthers acts 
membrane wetting agent, calcium chelator. This strategy is under different stages for 
clinical compounds with different TPPs. TBRIATM, an oral calcitonin formulation for 
osteoporosis based on PeptelligenceTM have completed phase 3 clinical trial and got NDA 
status from FDA [169, 170].      
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CHAPTER 5.    CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Proteins and peptides play crucial roles in governing several biochemical 
processes in human body. Emil Behring started first use of antibody-based therapy back 
in early 1890. He with his friend Erich Wernicke were successful in developing a useful 
therapeutic serum against diphtheria. Then comes Frederick Banting who first used 
insulin as non-antibody-based therapy to treat diabetes in 1922. These initial successes 
were limited due to unavailability of large-scale peptide synthesis process as the early 
protein-peptides were isolated from animal sources.  
 
The paradigm shift of TPPs from laboratory bench to industry happened after 
discovery of recombinant DNA technology and solid-phase protein synthesis which 
allowed large scale of synthesis of TPPs. A variety of peptides and proteins are currently 
in use for treating different diseases but mostly through the parenteral route. On the other 
hand, oral route is most preferred route for administration due to patient compliance and 
ease of administration. Therapeutic potential of TPPs is hampered by systemic instability 
in GIT and poor absorption through intestinal epithelia when administered orally. To 
exert its activity, TPPs must remain stable and active before reaching to the systemic 
circulation. In last few years, significant efforts were made for enhancing bioavailability 
orally administered peptides and proteins. A handful of absorption enhancers and enzyme 
inhibitors, structural modifications and carrier systems were developed tackle systemic 
instability and increase bioavailability of TPPs. These strategies have met with initial 
success but very few of them have made to the clinics. This certainly indicates the 
challenges in front of oral delivery of TPPs.  
 
For achieving better result, it is necessary to understand the factors that affect GIT 
stability and permeation across the intestinal epithelia of TPPs. Current efforts are mostly 
directed to protect enzymes from acidic environment and proteolytic enzymes and 
enhancing their permeation. Most of the technologies, met with some success, have 
combined few strategies rather than using a single method. Though several studies have 
conducted on animals very few of them were done on human. Toxicity profile of 
formulation excipients in human should also be noted while developing a successful TPP 
formulation. Taking all these into consideration may lead to safer and successful 
development of orally administered TPP formulations. 
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